Form 4: H.B. Fuller Executive VP and CFO Reports Changes in Beneficial Ownership
SEC Form 4
Executive VP and CFO of H.B. Fuller, John J. Corkrean, reports changes in beneficial ownership of company stock and derivative securities as of January 31, 2025.
Summary
- John J. Corkrean, Executive VP and CFO of H.B. Fuller, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- The report indicates ownership of 52,196 shares of common stock.
- Corkrean also holds various employee stock options with exercise prices ranging from $43.48 to $77.72 and expiration dates between 2026 and 2035.
- He also owns phantom units and restricted stock units that convert into common stock on a 1-for-1 basis.
- The reported transactions include the acquisition of 2,502.39 phantom units on January 31, 2025, at a price of $63.13.
- The report also details the vesting schedules for certain stock options and restricted stock units.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The executive's continued holding of stock and options is a mildly positive signal.
Positives
- The reporting of beneficial ownership changes provides transparency to investors.
- The executive's continued holding of company stock and options suggests confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing is consistent with standard practices for publicly traded companies.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are common across publicly traded companies like H.B. Fuller.
- Companies such as 3M, Avery Dennison, and Sherwin-Williams also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules and exercise prices of the options are within typical ranges for executive compensation plans in comparable companies.
Stakeholder Impact
- Shareholders can use this information to understand the alignment of management's interests with their own.
- Employees holding similar stock options or restricted stock units may be interested in the vesting schedules and exercise prices.
Key Dates
| Date | Description |
|---|---|
| 05/17/2017 | Date of grant for employee stock options exercisable until 05/17/2026 at $43.48. |
| 01/24/2020 | Date of grant for employee stock options exercisable until 01/24/2029 at $45.05. |
| 01/24/2021 | Date of grant for employee stock options exercisable until 01/24/2030 at $48.35. |
| 01/26/2018 | Date of grant for employee stock options exercisable until 01/26/2027 at $50.1. |
| 01/25/2019 | Date of grant for employee stock options exercisable until 01/25/2028 at $53.57. |
| 01/24/2023 | Date of grant for employee stock options exercisable until 01/24/2032 at $72.94. |
| 01/24/2024 | Date of grant for employee stock options exercisable until 01/24/2033 at $68.17 and restricted stock units vesting until 01/24/2026. |
| 01/27/2022 | Date of grant for employee stock options exercisable until 01/27/2031 at $51.89. |
| 01/27/2026 | Date of grant for employee stock options exercisable until 01/27/2035 at $64.28 and restricted stock units vesting until 01/27/2028. |
| 01/26/2025 | Date of grant for employee stock options exercisable until 01/26/2034 at $77.72 and restricted stock units vesting until 01/26/2027; also the transaction date for the acquisition of phantom units. |
| 01/31/2025 | Date of the reported transaction. |
| 02/03/2025 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.